BioNTech (NASDAQ:BNTX) reported quarterly losses of $(1.82) per share which beat the analyst consensus estimate of $(2.02) by 9.9 percent. This is a 28.17 percent decrease over losses of $(1.42) per share from the same period last year. The company reported quarterly sales of $192.23 million which beat the analyst consensus estimate of $177.40 million by 8.36 percent. This is a 5.65 percent decrease over sales of $203.74 million the same period last year.